Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (2128)	10/6/1997 5:48:00 AM
From: Henry Niman	of 6136

Rick, I think that you are right on the money about the durability and potency og AGPH. I haven't followed the company that closely lately and my general take of Viracept goes back to some of your posts on its superior resistance profiles. In view of the Jesse Eisinger article in thestreet.com I decided to revist the issue. I did think that thestreet got out the story first (regarding the less than ideal ability of advanced patients to be able to switch PIs after starting on Viracept) and after I dug a little I found that the Newark story was in fact consistant with AGPH's data on non-naive patients. The question that I asked, that really hasn't been answered on this board concerns in vivo data. I know that in vitro data suggests that Viracept has advantages for being the first PI (vis-a-vis cross resistance to other PIs), but I wasn't sure if there was patient data supporting the in vitro data (if a naive to PI patient begins on a PI other than Viracept, what happens when they switch to Viracept - I assume that 100% are not successful, but is the rate significantly lower than a switch from another PI to Viracept?).

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next